![clincloud](https://investor.igcpharma.com/wp-content/uploads/2024/04/PR-AD_03-min-1024x1024.jpg)
December 1, 2022
IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer Disease
Facebook
Twitter
LinkedIn